(Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new EQ504 preclinical data have been accepted for poster ...
Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence ...
Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. — Image: National Institutes of Health, Public Domain Scanning electron ...
Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in cohort of patients with psoriasis Full dataset to expand on previously announced ...
This strategic partnership with WuXi XDC represents a major milestone for Akari and a powerful validation of our novel PH1 payload technology,” said Abizer Gaslightwala, President and Chief Executive ...
SAN DIEGO--(BUSINESS WIRE)--Valora Therapeutics Inc. (“Valora”), a biotechnology company pioneering a novel approach to immunotherapy, today announced the successful closing of its seed funding round.
New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of Neuroblastoma Study Illustrates Potential to Activate the Immune System Even in ...
Immune thrombocytopenia (ITP) is a chronic autoimmune disorder associated with platelet destruction and increased bleeding risk, substantial economic burden, and impairment of health-related quality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results